Clinical Trial Update: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the efficacy and safety of once-weekly semaglutide added to SGLT-2 inhibitors versus placebo in adults with type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2019-08-20